Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: The Early Diabetes Intervention Program

Diabetes Care

Volumn 29, Issue 9, 2006, Pages 2095-2101

  Kirkman, M Sue ^a,b,e   Shankar, R Ravi ^a   Shankar, Sudha ^a   Shen, Changyu ^a   Brizendine, Edward ^a   Baron, Alain ^a,c   McGill, Janet ^d  

^a INDIANA UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; INSULIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; TEST MEAL; TREATMENT OUTCOME;

ACARBOSE; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 33845286208     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0061     Document Type: Article

References (22)

1. UK Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
2. Polonsky KS, Sturis J, Bell G: Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the β cell to compensate for insulin resistance. N Engl J Med 334:777-783, 1996
3. Kahn SE: The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058, 2001
4. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
5. Porte DL, Kahn SE: β-Cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 50:S160-S163, 2001
6. Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 15:815-819, 1992
7. Kanauchi M, Nakajima M, Saito Y, Kanauchi K: Pancreatic β-cell function and insulin sensitivity in Japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. Metabolism 52:476-481, 2003
8. Harris M, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria. Diabetes Care 20:1859-1862, 1997
9. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
10. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A: β-Cell adaptation and decompensation during progression of diabetes. Diabetes 50:S154-S159, 2001
11. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H: Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52:581-587, 2003
12. Ryan EA, Imes S, Wallace C: Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27:1028-1032, 2004
13. Park S, Choi SB: Induction of long-term normoglycemia without medication in Korean type 2 patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 19:124-130, 2003
14. Precose package insert. West Haven, CT, Bayer, 2004
15. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623-634, 1999
16. 1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care 24:465-471, 2001
17. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 273:E214-E223, 1979
18. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
20. Chaisson J-L, Josse RG, Gomis R, Hanefield M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM trial. Lancet 359-2072-2077, 2002
21. Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB: Effect of lowering postprandial hyperglycemia on older people with impaired glucose tolerance. Am J Physiol 287:E906-E911, 2004
22. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001